BIOMARIN PHARMACEUTICAL INC (BMRN)
US09061G1013 - Common Stock
BIOMARIN PHARMACEUTICAL INC
NASDAQ:BMRN (4/22/2024, 4:53:45 PM)
After market: 89.49 0 (0%)89.49
+0.86 (+0.97%)
Company Profile
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in Novato, California and currently employs 3,082 full-time employees. The firm's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Roctavian (valoctocogene roxaparvovec) and Voxzogo (vosoritide). The Roctavian is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. The Company’s clinical development programs include BMN 331, an AAV5 mediated gene therapy for people living with Hereditary Angioedema (HAE) and BMN 255 is a small-molecule therapy that is designed to treat hyperoxaluria in chronic liver disease.
Company Info
BIOMARIN PHARMACEUTICAL INC
105 Digital Dr
Novato CALIFORNIA 94901
P: 14155066700
CEO: Jean-Jacques Bienaime
Employees: 3082
Website: https://www.biomarin.com/
BMRN News
3 days ago - Market News VideoNotable Friday Option Activity: TWLO, VRT, BMRN
12 days ago - BioMarin Pharmaceutical Inc.BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host...
14 days ago - ChartmillDon't overlook NASDAQ:BMRN—a stock with solid growth prospects and a reasonable valuation.Investors seeking growth at a reasonable cost should explore BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN).
a month ago - The Motley Fool4 Extraordinary Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull MarketAlthough the Nasdaq Composite is galloping to record highs, amazing deals among growth stocks can still be uncovered.
a month ago - BioMarin Pharmaceutical Inc.New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO®...
2 months ago - BioMarin Pharmaceutical Inc.BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial...
BMRN Twits
Here you can normally see the latest stock twits on BMRN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
